Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-06-21
2011-06-21
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024100, C536S024310, C435S006120, C435S325000, C435S375000, C514S04400A
Reexamination Certificate
active
07964717
ABSTRACT:
RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.
REFERENCES:
patent: 6140126 (2000-10-01), Bennett et al.
patent: 6284741 (2001-09-01), Werther et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2003/0158130 (2003-08-01), Gleave et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2006/0003322 (2006-01-01), Bentwich
patent: WO 00/49937 (2000-06-01), None
patent: WO 00/69454 (2000-11-01), None
patent: WO 01/05435 (2001-01-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 02/22635 (2002-03-01), None
patent: WO 02/22642 (2002-03-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 03/062421 (2003-07-01), None
Zangemeister et al. A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xl Expression Efficiently Induces Apoptosis in Tuymor Cell. Clinical Cancer Research, 2000, vol. 6: 2547-2555.
Zhang et al. Targeted Gene Silencing by Small Interfering RNA based Knock-down TEchnology. Current Pharmaceutical Biotechnology 2004, vol. 5, p. 1-7.
Mahato et al. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opin. Deliv. 2005, vol. 2(1): 3-28.
Scherer et al. Approaches for the Sequence-specific knockdown of mRNA (Nat. Biotechnol., 2003, 21(12), pp. 1457-1465).
Leirdal et al. Gene silencing in mammalian cells by preformed small RNA duplexes. Biochem and Biophys Res Comm 295 (2002) 744-748.
Agami , RNAi and related mechanisms and their potential use for therapy, Current Opinion in Chemical Biology, 2002, pp. 829-834, vol. 6, Publisher: Current Biology Ltd, London, GB XP00295888.
Brummelkamp et al., A system for stable expression of short interfering RNAs in mammalian cells, Science, 2002, pp. 550-553, vol. 296, No. 5567, Publisher: American Association for the Advancement of Science, US, XP002234902.
Calero et al., Apolipoprotein J (Clusterin) and Alzheimer's Disease, Microscopy Research and Technique, 2000, pp. 305-315, vol. 50, No. 4, XP009021345.
Choi-Miura et al., Relationship Between Multifunctional Protein “Clusterin” and Alzheimer Disease, Neurobiology of Aging, 1996, pp. 717-722, vol. 17, No. 5, XP001146408.
Demir et al., Use of RNA Interference (RNAi) to Disrupt C-Kit Gene Expression in Malignant Human Hematopoietic and Neuroepithelial Cells, Blood, 2000, p. 378B, vol. 96, No. 11, Part 2, Publisher: W. B. Saunders Company, Orlando, FL, US, Abstract #5389, XP009004894.
Gleave et al., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2, to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, pp. 39-49, vol. 58, XP002262320.
Gleave et al., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, pp. 145-158, vol. 20, No. 2, XP 009021411.
Hojoh , RNA interference (RNAi) induction with various types of synthetic oligonucleotide duplexes in cultered human cells, FEBS Letters, 2002, pp. 195-199, vol. 521, No. 1-3, Publisher: Elsevier Science Publishers, Amsterdam, NL XP004362164.
Jones et al., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, pp. 427-431, vol. 34, XP002262319.
Koch-Brandt et al., Clusterin: A Role in Cell Survival in the Face of Apoptosis?, Process in Molecular and Subcellar Biology, 1996, pp. 130-149, vol. 16, XP009021385.
Miyake et al., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo, Clinical Cancer Research, 2000, pp. 1655-1663, vol. 6, No. 5, Publisher: The American Association for Cancer Research, US, XP000960694.
Miyake et al., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity., International Journal of Urology, 2001, pp. 337-349, vol. 8, No. 7, XP002262321.
Paddison et al., Stable suppression of gene expression by RNAi in mammalian cells, Proceedings of the National Academy of Sciences of USA, 2002, pp. 1443-1448, vol. 99, No. 3, Publisher: National Academy of Science, XP002958887.
Rosenberg et al., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, pp. 633-645, vol. 27, No. 7, XP001002844.
Sensibar et al., Prevention of Cell Death Induced by Tumor Necrosis Factor α in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin), Cancer Research, 1995, pp. 2431-2437, vol. 55, Publisher: American Association for Cancer Research, Baltimore, MD, US, XP002930082.
Sharp, RNAi and double-strand RNA, Genes and Development, 1999, pp. 139-141, vol. 13, No. 2, Publisher: Cold Spring Harbor Laboratory Press, New York, US, XP002171268.
Strocchi et al., Neuronal loss up-regulates clusterin mRNA in living neurons and glial cells in the rat brain, NeuroReport, 1999, pp. 1789-1792, vol. 10, No. 8, Publisher: Rapid Communications of Oxford, Oxford, GB, XP009017327.
Sui et al., A DNA vector-based RNAi technology to suppress gene expression in mammalian cells, Proceddings of the National Academy of Sciences of USA, 2002, pp. 5515-5520, vol. 99, No. 8, Publisher: National Academy of Science, Washington, US, XP002964701.
Tuschl et al., Targeted mRNA degradation by double-stranded RNA in vitro, Genes and Development, 1999, pp. 3191-3197, vol. 13, No. 24, Publisher: Cold Spring Harbor Laboratory Press, New York, US, XP002183118.
Ueda , RNAi: A new technology in the post-genomic sequencing era, Journal of Neurogenetics, 2001, pp. 193-204, vol. 15, No. 3/4, Publisher: Elsevier, Amsterdam, NL, XP001147227.
Wilson et al., Clusterin is a secreted mammalian chaperone, Trends in Biochemical Sciences, 2000, pp. 95-98, vol. 25, No. 3, Publisher: Elsevier Publication, Cambridge, EN, XP004202536.
Wong et al., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry,1994, pp. 917-925, vol. 227, No. 3, XP 001146404.
Zellweger et al., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of 2′O-(2-Methoxy)Ethyl Chemistry, Journal of Pharmacology and Expermental Therapeutics, 2001, pp. 934-940, vol. 298, No. 3, XP002262318.
Chako et al., Double-stranded ribonucleic acid decreases C6 rat glioma cell numbers: Effects on insulin-like growth factor I gene expression and action, Endocrinology, Oct. 2000, vol. 141, No. 10, pp. 3546-3555.
Pavelic et al., Insulin-like growth factor family and combined antisense approach in therapy of lung carcinoma, Molecular Medicine, Mar. 2002, vol. 8, No. 3, pp. 149-157.
Miyake, et al., Castration-Induced Up-Regulation of Insulin-Like Growth Factor Binding Protein-5 Potentiates Insulin-Like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models, Cancer Research, Jun. 1, 2000, pp. 3058-3064, vol. 60.
Davies et al., Mutations of the BRAF gene in hum
Beraldi Eliana
Gleave Martin E.
Gonos Efstathios
Jansen Burkhard
Signaevsky Maxim
Chong Kimberly
Larson & Anderson LLC
The University of British Columbia
LandOfFree
RNAi probes targeting cancer-related proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi probes targeting cancer-related proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi probes targeting cancer-related proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2706108